Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Cintas Q4 Earnings

  Cintas (NASDAQ:CTAS) reported its Q4 earnings results on Thursday, July 14, 2022 at 09:22 AM. Here's what investors need to know about the announcement.
byBenzinga Insights
July 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

Cintas (NASDAQ:CTAS) reported its Q4 earnings results on Thursday, July 14, 2022 at 09:22 AM.

Here’s what investors need to know about the announcement.

Earnings

Cintas beat estimated earnings by 5.24%, reporting an EPS of $2.81 versus an estimate of $2.67.

Revenue was up $239.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.26 which was followed by a 2.26% increase in the share price the next day.

Here’s a look at Cintas’s past performance:

 

Quarter Q3 2022 Q2 2022 Q1 2022 Q4 2021
EPS Estimate 2.43 2.65 2.75 2.30
EPS Actual 2.69 2.76 3.11 2.47
Revenue Estimate 1.91B 1.90B 1.87B 1.82B
Revenue Actual 1.96B 1.92B 1.90B 1.84B

To track all earnings releases for Cintas visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Organic Growth And Innovation Drive YoY Increase In Cannabis Producer Organigram’s Q4 Revenue And Adjusted EBITDA

By Jelena Martinovic
December 19, 12:41 PM
Canadian cannabis producer Organigram Holdings reported an 11% year-over-year increase in net revenue for the fourth quarter, reaching C$A161.6 million ($121 million). The company credited the growth to its focus on innovative products that meet consumer demand for convenience, such as pre-rolls and edibles. The increase in revenue contributed to a 71% rise in adjusted EBITDA to nearly CA$6m for the quarter, compared with the same period in 2022. Organigram's adjusted gross margin was CA$40.2m, up 20% on 2022. The company also reported a net loss of CA$248.6m, compared with CA$14.3m in 2022, due to impairments on property, plant and equipment, intangibles and goodwill. Organigram said it expects improved margins in future as efficiency gains from facility upgrades and expansion into higher-margin categories such as craft flower and vapes bear fruit.

OGI